Human Immunodeficiency Virus Clinical Trial
Official title:
iTransition: Pilot Testing a Multilevel Technology Based Intervention to Support Youth Living With HIV From Adolescent to Adult Care
Verified date | October 2023 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Youth living with HIV are at high risk of falling out of care when they transition from pediatric to adult care. The investigators are proposing to develop a mobile app to help both clinical providers and patients navigate this process.
Status | Active, not recruiting |
Enrollment | 52 |
Est. completion date | June 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: For YLH Historical Control Group - YLH (regardless of gender/assigned sex at birth) age = 18 years; - Has plan for HCT within next 6 months; - Enrolled in care at Grady IDP pediatric/adolescent clinic or CHOP AI/SI clinics. For YLH iTransition Intervention Group - YLH (regardless of gender/assigned sex at birth) age = 18 years; - Has plan for HCT within next 6 months; - Enrolled in care at Grady IDP pediatric/adolescent clinic or CHOP AI/SI clinics; - Owns a smartphone and/or tablet - Reports consistent internet access (defined as no lapse >24 hours in last 6 months) via their smartphone or tablet. For Provider Group - Staff member at Grady IDP (pediatric/adolescent clinic, adult women's clinic, and/or adult men's clinic), CHOP AI/SI clinics, UPHS: HUP or Presby infectious disease clinics; - Works with transitioning YLH; - Access to internet via any device (e.g., smartphone, tablet, computer); - Endorse participation in the HCT process. For Transition Champion Group - Staff member at Grady IDP (pediatric/adolescent clinic, adult women's clinic, and/or adult men's clinic), CHOP AI/SI clinics, UPHS: HUP or Presby infectious disease clinics; - Works with transitioning YLH; - Endorse participation in the HCT process; - Access to internet via any device (e.g., smartphone, tablet, computer); - Nominated by clinic staff where employed to be iTransition intervention point person (champion). Exclusion Criteria For YLH Historical Control Group - Youth who are <18 years old; - Youth who are not living with HIV; - Transition is not expected (from pediatric/adolescent to adult care) within the next 6 months; - Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder) that would impair the individual's ability to provide true informed consent or participate in the study activities; - Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior) at the time of consent. For YLH iTransition Intervention Group - Youth who are <18 years old; - Youth who are not living with HIV; - Transition is not expected (from pediatric to adult care) within the next 6 months; - Does not own smartphone/tablet and has inconsistent internet access (i.e. has had one or more lapse >24 hrs in the last three months); - Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder) that would impair the individual's ability to provide true informed consent or participate in the study activities; - Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior) at the time of consent. For Provider Group - Not a staff member at Grady IDP, CHOP SI/AI, UPHS: HUP or Presby infectious disease clinics; - Does not work with transitioning YLH; - Does not have access to internet via any device (e.g., smartphone, tablet, computer). For Transition Champion Group - Not a staff member at Grady IDP, CHOP SI/AI, UPHS: HUP or Presby infectious disease clinics; - Does not work with transitioning YLH; - Does not have access to internet via any device (e.g., smartphone, tablet, computer). |
Country | Name | City | State |
---|---|---|---|
United States | Grady Hospital | Atlanta | Georgia |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | University of Pennsylvania Health System - HUP and Presby infectious disease clinics | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Linkage to adult care | Defined dichotomously as having one completed adult clinic appointment or not. | 18 month post-intervention | |
Secondary | Change in Care retention | Defined dichotomously as having one completed medical visit in each 6-month period. | Baseline, 6 month post-intervention, 12 month post-intervention, 18-month post-intervention | |
Secondary | Change in viral suppression | Viral suppression is defined as <200 copies/ml blood at 1 year post-baseline. | Baseline, 1-year post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |